Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants

被引:48
作者
Barbaro, Danielle
Boni, Giuseppe
Meucci, Giuseppe
Simi, Umberto
Lapi, Paola
Orsini, Paola
Pasquini, Cristina
Turco, Anna
Mariani, Giuliano
机构
[1] Spedali Riuniti Livorno, Endocrinol Sect, I-57100 Livorno, Italy
[2] Univ Pisa, UO Nucl Med, Pisa, Italy
关键词
rhTSH; differentiated thyroid cancer; radiometabolic treatment;
D O I
10.1097/00006231-200608000-00005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To investigate whether recombinant human thyroid-stimulating factor (rhTSH) is effective for the radiometabolic ablation of post-surgery thyroid remnants, using low doses of I-131. Patients and methods The study included two groups of patients enrolled consecutively: group 1 consisted of 52 patients with papillary cancer or minimally invasive follicular cancer (stage I and 11), and group 2 consisted of 41 patients with the same stage of disease. All patients underwent a total thyroidectomy. Group 1 received 1.11 GBq (30 mCi) I-131 for post-surgical remnants ablation with the aid of rhTSH, while group 2, in the hypothyroid state, received the same amount of radioiodine. To minimize iodine interference, all patients remained on a low iodine diet for 2 weeks and L-thyroxine (L-T4) was stopped for 4 days in the group of patients treated with the aid of rhTSH. To investigate I-131 uptake in this group, a tracer dose was administered 3 h after the second injection of rhTSH and the uptake was evaluated at 24 h just before administration of the therapeutic dose. I-131 was also measured in the patients treated in the hypothyroid state just before the therapeutic dose was given. Results After 1 year both groups were studied by using whole-body scintigraphy (WBS) and measuring thyroglobulin after rhTSH. In group 1, WBS was negative in 76.9% (40 patients), while thyroglobulin-stimulated levels were < 1.0 ng(.)ml(-1) in 86.5% (45 patients). In Group 2, WBS was negative in 75.6% (31 patients), while thyroglobulin-stimulated levels were < 1 ng(.)ml(-1) in 78.0% (32 patients). I-131 uptake was 2.29 +/- 0.45 in the group treated with the aid of rhTSH, and 3.30 +/- 0.7 in the group treated in the hypothyroid state (P=0.2). No patients treated with the aid of rhTSH and with the short stoppage of L-T4 experienced symptoms of hypothyroidism, and free thyroxine (FT4) and thyroid-stimulating hormone levels remained normal. Conclusions Our data confirm that, when the interference of iodine is minimized, rhTSH is highly effective for the treatment of post-surgical thyroid remnants using a low dose of I-131.
引用
收藏
页码:627 / 632
页数:6
相关论文
共 23 条
[1]  
Adler M L, 1998, Endocr Pract, V4, P282
[2]   Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation [J].
Barbaro, D ;
Boni, G ;
Meucci, G ;
Simi, U ;
Lapi, P ;
Orsini, P ;
Pasquini, C ;
Piazza, F ;
Caciagli, M ;
Mariani, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) :4110-4115
[3]   Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone [J].
Berg, G ;
Lindstedt, G ;
Suurküla, M ;
Jansson, S .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (01) :44-52
[4]   Prognosis and treatment of brain metastases in thyroid carcinoma [J].
Chiu, AC ;
Delpassand, ES ;
Sherman, SI .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (11) :3637-3642
[5]  
de Keizer B, 2004, J NUCL MED, V45, P1549
[6]   NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA [J].
DEGROOT, LJ ;
KAPLAN, EL ;
MCCORMICK, M ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :414-424
[7]  
Duick Daniel S, 2003, Endocr Pract, V9, P204
[8]   Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells [J].
Kogai, T ;
Endo, T ;
Saito, T ;
Miyazaki, A ;
Kawaguchi, A ;
Onaya, T .
ENDOCRINOLOGY, 1997, 138 (06) :2227-2232
[9]  
Löffler M, 2003, NUKLEARMED-NUCL MED, V42, P240
[10]  
MARUCA J, 1984, J NUCL MED, V25, P1089